Search Results - Luis Paz-Ares

Refine Results
  1. 1
    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain

    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain by Luis Paz-Ares, Luis Manso, Guillermo De Velasco

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects by Solange Peters, Roy S Herbst, Martin Reck, Luis Paz-Ares

    Published 2022-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

    KRAS oncogene in lung cancer: focus on molecularly driven clinical trials by Emmanuelle Kempf, Benoît Rousseau, Benjamin Besse, Luis Paz-Ares

    Published 2016-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy

    Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy by Sergio González Rubio, Sergio González Rubio, Nuria Montero Pastor, Nuria Montero Pastor, Carolina García, Víctor G. Almendro-Vedia, Víctor G. Almendro-Vedia, Irene Ferrer, Irene Ferrer, Paolo Natale, Paolo Natale, Luis Paz-Ares, Luis Paz-Ares, Luis Paz-Ares, Luis Paz-Ares, M. Pilar Lillo, Iván López-Montero, Iván López-Montero

    Published 2018-11-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Durvalumab in NSCLC: latest evidence and clinical potential

    Durvalumab in NSCLC: latest evidence and clinical potential by Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares

    Published 2018-10-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Treating -mutant NSCLC: latest evidence and clinical consequences

    Treating -mutant NSCLC: latest evidence and clinical consequences by Pilar Garrido, María Eugenia Olmedo, Ana Gómez, Luis Paz Ares, Fernando López-Ríos, Juan Manuel Rosa-Rosa, José Palacios

    Published 2017-09-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts)

    464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts) by Luis Paz-Ares, Santiago Ponce Aix, Alejandro Navarro, Reyes Bernabe, Maria Eugenia Olmedo, Trigo Jose Manuel, Jon Zugazagoitia Fraile

    Published 2021-11-01
    Article
    Save to List
    Saved in:
  8. 8
    368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors

    368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors by Magnus Jaderberg, Victor Levitsky, Lukasz Kuryk, Sandeep Kumar, Alexander Shoushtari, Anne-Sophie Moller, Luis Paz Ares, Erik Digman Wiklund

    Published 2021-11-01
    Article
    Save to List
    Saved in:
  9. 9
    Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

    Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry by Ángela Marrugal, Irene Ferrer, Maria Dolores Pastor, Laura Ojeda, Álvaro Quintanal-Villalonga, Amancio Carnero, Sonia Molina-Pinelo, Luis Paz-Ares

    Published 2019-07-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models

    Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models by M. Teresa Agulló-Ortuño, Esther Mancebo, Montserrat Grau, Juan Antonio Núñez Sobrino, Luis Paz-Ares, José A. López-Martín, Marta Flández

    Published 2023-08-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma

    Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma by Ángela Marrugal, Irene Ferrer, David Gómez-Sánchez, Álvaro Quintanal-Villalonga, María Dolores Pastor, Laura Ojeda, Luis Paz-Ares, Sonia Molina-Pinelo

    Published 2021-03-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

    Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy by Ángela Marrugal, Irene Ferrer, Álvaro Quintanal-Villalonga, Laura Ojeda, María Dolores Pastor, Ricardo García-Luján, Amancio Carnero, Luis Paz-Ares, Sonia Molina-Pinelo

    Published 2023-09-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data

    462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data by Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus

    Published 2021-11-01
    Article
    Save to List
    Saved in:
  14. 14
    MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

    MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma by Irene Ferrer, Álvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Jose Manuel Garcia-Heredia, Marco Perez, Rocío Suárez, Santiago Ponce-Aix, Luis Paz-Ares, Amancio Carnero

    Published 2018-08-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

    361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers... by Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus

    Published 2020-11-01
    Article
    Save to List
    Saved in:
  16. 16
    A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.

    A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. by Bárbara Angulo, Esther Conde, Ana Suárez-Gauthier, Carlos Plaza, Rebeca Martínez, Pilar Redondo, Elisa Izquierdo, Belén Rubio-Viqueira, Luis Paz-Ares, Manuel Hidalgo, Fernando López-Ríos

    Published 2012-01-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

    Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma by Patrick Schöffski, Vincente Guillem, Margarita Garcia, Fernando Rivera, Josep Tabernero, Martin Cullell, Jose Antonio Lopez-Martin, Patricia Pollard, Herlinde Dumez, Xavier Garcia del Muro, Luis Paz-Ares

    Published 2009-03-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer by Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares

    Published 2023-06-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

    Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study by Hope S. Rugo, Peter Kabos, J. Thad Beck, Guy Jerusalem, Hans Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J. Chisamore, Sonya C. Chapman, Anwar M. Hossain, Yanyun Chen, Sara M. Tolaney

    Published 2022-11-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. by Edward Wolin, Alain Mita, Amit Mahipal, Tim Meyer, Johanna Bendell, John Nemunaitis, Pam N Munster, Luis Paz-Ares, Ellen H Filvaroff, Shaoyi Li, Kristen Hege, Hans de Haan, Monica Mita

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: